Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Conference Roundup > Tecnis Eyhance leads to good visual and refractive outcomes in post-refractive surgery eyes
  • Conference Roundup

Tecnis Eyhance leads to good visual and refractive outcomes in post-refractive surgery eyes

Ophthalmology 360

At the American Society of Cataract and Refractive Surgery Annual Meeting, Abinaya Thenappan, MD, of the Cleveland Eye Clinic, spoke with Ophthalmology 360 about the Tecnis Eyhance and found it was a “strong candidate” for post-refractive eyes.

Abinaya Thenappan, MD:

Hi, my name is Abinaya Thenappan. I’m a cataract and refractive fellow with Dr. Wiley and Dr. Bafna at the Cleveland Eye Clinic. I’m here to share a little bit about our results, our experience using the Tecnis Eyhance in post-refractive eyes. As we know, patients who have had a history of refractive surgery are often very motivated to regain their spectacle independence after cataract surgery. The power calculations can be a little bit tricky in these eyes, and enhancement rates can vary widely, anywhere from 4% to 50% depending on the study.

One lens that is of particular interest in this population is the Tecnis Eyhance for a couple of reasons. One, it has a small central add power that theoretically increases the depth of focus and offers a wider landing strip, if you will. It also has negative spherical aberration, which counteracts the positive spherical aberration that is seen in post-myopic LASIK and RK eyes, corneas. Theoretically, the Tecnis Eyhance is a very strong candidate in these post-refractive eyes for these 2 reasons. It has a little bit better visual optical quality theoretically, and more refractive forgiveness. What we did to test this is we looked at 339 eyes of 227 patients that had a history of refractive surgery and subsequently underwent Eyhance implantation. This was a retrospective review of consecutive case records from our clinic.

What we found was, at postop month 1, 89% of them had achieved an uncorrected visual acuity of 20/30 or better. By postop month 3, 91% of them had achieved a corrected distance visual acuity of 20/30 or better. Our enhancement rate was 1.2% overall, and the mean spherical equivalent that these eyes landed at was 72% of them were about plus minus half the diopter. Overall, these early outcomes suggest that the Tecnis Eyhance is a strong candidate in these post-refractive eyes. It offers a level of refractive forgiveness that is very valuable in these eyes. Moving forward, we’re hoping to compare this to a group of post-refractive eyes that received a standard Tecnis monofocal to see how they compare.

Of course, there are some limitations with the study, as with any study. We didn’t have very long follow-up. We also didn’t compare to a standard monofocal yet. We don’t have that data quite yet, and it would have been nice to have some sort of wavefront analysis or contrast sensitivity. These are some future directions that we’re brainstorming, but overall, we’re excited with our initial results and excited to share them with you.

Share

Related Content

  • The Interventional Glaucoma Project

Improving Patient Experience and Practice Workflow With an Interventional Glaucoma Approach

  • The Interventional Glaucoma Project

Data-Driven Focus on Interventional Glaucoma Care

  • Conference Roundup

Cryopreserved amniotic membrane significantly improves ocular surface integrity in patients with severe keratoconjunctivitis sicca and neurotrophic keratopathy

  • Conference Roundup

CAM360 with a collagen shield provides rapid epithelial healing with better tolerability and safety than when used with bandage contact lenses

  • Conference Roundup

Enhanced monofocal IOLs provide better intermediate vision with no rings or dysphotopsia

  • Conference Roundup

Phase 1/2 CLARA study shows AURN001 improves BCVA compared with standard of care for corneal endothelial dysfunction

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon